1-4 of 4
David Hall
Close
Sort by
Journal Articles

Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: A Report from the Children's Oncology Group

Elliot Stieglitz, Alex Lee, Steven P. Angus, Christopher Davis, Donald Barkauskas, David Hall, Scott C. Kogan, Julia Meyer, Steven D. Rhodes, Xiaoling Xuei, Kevin Shannon, Mignon L. Loh, Elizabeth Fox, Brenda J. Weigel
Journal: Blood
Blood (2023) 142 (Supplement 1): 74.
https://doi.org/10.1182/blood-2023-173153
Published: 2023
Journal Articles

MEK Inhibition Demonstrates Activity in Relapsed, Refractory Patients with Juvenile Myelomonocytic Leukemia: Results from COG Study ADVL1521

Elliot Stieglitz, Mignon L. Loh, Julia Meyer, Chujing Zhang, Donald A Barkauskas, David Hall, Elizabeth Fox, Brenda J. Weigel
Journal: Blood
Blood (2021) 138 (Supplement 1): 3679.
https://doi.org/10.1182/blood-2021-144850
Published: 2021
Journal Articles

Toxicity Profile of Brentuximab Vedotin in Combination with Chemotherapy for Newly Diagnosed Patients with ALK+ ALCL: A Children's Oncology Group Study ANHL12P1

Eric J Lowe, MD, Anne Reilly, MD, Catherine M. Bollard, MD, Donald A Barkauskas, Allen B Buxton, David Hall, Lauren Saguilig, John T. Sandlund, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1625.
https://doi.org/10.1182/blood-2018-99-118450
Published: 2018
Journal Articles

Differential Activation of Stress Kinases Pathways and Elaboration of Inflammatory Cytokines MCP-1 and RANTES by Major and Minor Group Rhinovirus.

Megan Wilson, Shashima Nakahara, BS, Laurel Benson, David Hall, PhD
Journal: Blood
Blood (2005) 106 (11): 3867.
https://doi.org/10.1182/blood.V106.11.3867.3867
Published: 2005